09 Sep 2021
Posted in Pharma
Diagnosed prevalent cases of cystic fibrosis to near 84,000 by 2030 in the 7MM, says GlobalData
Diagnosed prevalent cases of cystic fibrosis (CF) in the seven major markets (*7MM) are projected to increase from over 79,000 in 2020 to nearly 84,000 in 2030, with an annual growth rate (AGR) of 0.52%, according to GlobalData, a leading data and analytics company.
The company’s latest report, ‘Cystic Fibrosis (CF) – Epidemiology Forecast to 2030’, reveals that in 2030, the US will have the highest number of diagnosed prevalent cases of CF across the 7MM with nearly 42,000 cases, whereas Spain will have the lowest number with nearly 3,000 cases. In the *5EU, GlobalData estimates there will be over 37,000 diagnosed prevalent cases of CF in 2030.
Shaina Stacy, PhD, Senior Epidemiologist at GlobalData, says: “The rise in diagnosed prevalent cases is attributable to increases in the proportion of adults living with CF, significant and increasing historical trends in prevalence, and changes in the underlying population demographics.”
The US will have the highest number of CF cases in the 7MM, in part due to projected increases in the US population through 2030. Advancements in treatment made over the last several decades mean that people with CF are living longer. For instance, with the more widespread implementation of newborn screening programs in the 7MM, CF is also now detected, and treatment started, earlier.
Stacy concludes: “All 7MM have established national CF patient registries to drive efforts in CF education, care, and research. Although there is currently no cure for CF, additional research and drug development will continue to improve the quality of life and longevity of people with CF.”
*7MM: The US, 5EU (France, Germany, Italy, Spain, the UK) and Canada